✦ LIBER ✦

Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy

✍ Scribed by Edgardo Rivera; Frankie A. Holmes; Debra Frye; Vicente Valero; Richard L. Theriault; Daniel Booser; Ronald Walters; Aman U. Buzdar; Kapil Dhingra; Giuseppe Fraschini; Gabriel N. Hortobagyi

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 83 KB
Volume: 89
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(20001201)89:11<2195::aid-cncr7>3.0.co;2-w

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of paclitaxel plus carb

A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma

✍ Edith A. Perez; David W. Hillman; Philip J. Stella; James E. Krook; Lynn C. Hart 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 1 views

## BACKGROUND. This Phase II multicenter study evaluated the efficacy and toxicity of paclitaxel (200 mg/m 2 by 3-hour infusion) with carboplatin (area under the curve 6 mg/mL per minute) administered every 3 weeks as first-line therapy for women with metastatic breast carcinoma. ## METHODS. Eligi

Multicenter, Phase II study of capecitab

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

✍ Joanne L. Blum; Véronique Dieras; Patricia Mucci Lo Russo; John Horton; Olga Rut 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 1 views

A Phase II study of paclitaxel and ifosf

A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium

✍ Christopher J. Sweeney; Stephen D. Williams; David E. Finch; Richard Bihrle; Ric 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB 👁 2 views

## BACKGROUND. Cisplatin-based combination chemotherapy for patients with advanced transitional cell carcinoma (TCC) of the urothelium has limitations, and new therapies need to be evaluated. METHODS. Ifosfamide 1.0 gm/m 2 on Days 1-4 and paclitaxel 135 mg/m 2 by 24-hour infusion on Day 4 were ad

Oral estramustine and cyclophosphamide i

Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma : A phase II study

✍ Sergio Bracarda; Maurizio Tonato; Paolo Rosi; Verena De Angelis; Ettore Mearini; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 1 views

## BACKGROUND. Nearly all cases of metastatic prostate carcinoma progress, after hormonal ablation, to a hormone refractory status. To the authors' knowledge no standard chemotherapy for patients with hormone refractory prostate carcinoma (HRPC) exists. In a prospective study, the efficacy and toxi

Phase II study of paclitaxel and epirubi

Phase II study of paclitaxel and epirubicin as first-line treatment in patients with metastatic nonsmall cell lung carcinoma

✍ Giovanni L. Ceresoli; Stefania Dell'Oro; Paolo Passoni; Eugenio Villa 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

Phase II study of patients with metastat

Phase II study of patients with metastatic nonsmall cell carcinoma of the lung treated with paclitaxel by 3-hour infusion

✍ William J. Tester; Pamela Y. Jin; Deborah H. Reardon; Jeffrey B. Cohn; Martin H. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 1 views

## METHODS. Twenty patients with histologically proven Stage IV NSCLC were en-Pennsylvania. rolled in this study. All were treated on an outpatient basis with standard premedication followed by paclitaxel 200 mg/m 2 infused intravenously over 3 hours. Treatments were repeated every 21 days for a